|
SFRS2B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.52189372215616E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.11500047978086E-10 |
| Normal-vs-Stage2 |
1.74417999999621E-05 |
| Normal-vs-Stage3 |
6.40132391538373E-12 |
| Normal-vs-Stage4 |
1.62658775337832E-12 |
| Stage1-vs-Stage2 |
8.606000E-01 |
| Stage1-vs-Stage3 |
5.066500E-02 |
| Stage1-vs-Stage4 |
1.032660E-04 |
| Stage2-vs-Stage3 |
2.621600E-01 |
| Stage2-vs-Stage4 |
4.418400E-03 |
| Stage3-vs-Stage4 |
2.593800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.13906670154529E-12 |
| Normal-vs-AfricanAmerican |
1.980060E-03 |
| Normal-vs-Asian |
6.73250011296034E-10 |
| Caucasian-vs-AfricanAmerican |
6.773600E-01 |
| Caucasian-vs-Asian |
9.414200E-01 |
| AfricanAmerican-vs-Asian |
7.630000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.21185308852046E-12 |
| Normal-vs-Female |
1.59330326710005E-11 |
| Male-vs-Female |
1.220580E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.56430004902586E-10 |
| Normal-vs-Age(41-60Yrs) |
6.21336315731469E-12 |
| Normal-vs-Age(61-80Yrs) |
9.70410418688061E-11 |
| Normal-vs-Age(81-100Yrs) |
6.039400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.949800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.537970E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.953800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.691400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.566800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.724800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.375900E-02 |
| Classical-VS-Follicular |
8.213900E-02 |
| Classical-VS-Other |
8.190000E-01 |
| Classical-VS-Normal |
1.27790000803429E-10 |
| Tall-VS-Follicular |
9.797200E-04 |
| Tall-VS-Other |
3.522800E-01 |
| Tall-VS-Normal |
1.23949961405856E-10 |
| Follicular-VS-Other |
4.697600E-01 |
| Follicular-VS-Normal |
1.218430E-04 |
| Other-VS-Normal |
4.279500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.24480031522035E-10 |
| Normal-vs-N1 |
1.93955962402015E-13 |
| N0-vs-N1 |
3.319200E-03 |
|
|
